Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
View Patent ↗Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-γ-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.
1. An isolated, modified primate cystathionine-γ-lyase (CGL) enzyme comprising the following substitutions relative to a native human CGL amino acid sequence (SEQ ID NO: 1), wherein the modified enzyme has both cystinase and cysteinase activity, said substitutions being
alanine at position 193, glycine at position 311, valine at position 339, and serine at position 353.
2. The isolated, modified CGL enzyme of claim 1 , wherein the modified CGL enzyme is a modified human CGL enzyme.
3. The isolated, modified CGL enzyme of claim 1 , further comprising a heterologous peptide segment or a polysaccharide.
4. The isolated, modified CGL enzyme of claim 3 , wherein the heterologous peptide segment is an XTEN peptide, an IgG Fe, an albumin, or an albumin binding peptide.
5. The isolated, modified CGL enzyme of claim 3 , wherein the polysaccharide comprises polysialic acid polymers.
6. The isolated, modified CGL enzyme of claim 1 , wherein the enzyme is coupled to polyethylene glycol (PEG).
7. The isolated, modified CGL enzyme of claim 6 , wherein the enzyme is coupled to the PEG via one or more lysine residues.
8. A nucleic acid comprising a nucleotide sequence encoding the enzyme of claim 1 .
9. The nucleic acid of claim 8 , wherein the nucleic acid is codon optimized for expression in bacteria, fungus, insects, or mammals.
10. The nucleic acid of claim 9 , wherein the bacteria are E. coli.
11. The nucleic acid of claim 10 , wherein the nucleic acid comprises a sequence according to one of SEQ ID NOs: 81-95.
12. An expression vector comprising the nucleic acid of claim 8 .
13. A host cell comprising the nucleic acid of claim 8 .
14. The host cell of claim 13 , wherein the host cell is a bacterial cell, a fungal cell, an insect cell, or a mammalian cell.
15. A therapeutic formulation comprising the enzyme of claim 1 in a pharmaceutically acceptable carrier.
16. A method of treating a subject having or at risk of developing cystinuria comprising administering to the subject a therapeutically effective amount of the formulation of claim 15 .
17. The method of claim 16 , wherein the subject is maintained on a L-cystine and/or L-cysteine restricted diet.
18. The method of claim 16 , wherein the subject is maintained on a methionine-restricted diet.
19. The method of claim 16 , wherein the subject is maintained on a normal diet.
20. The method of claim 16 , wherein the subject is a human patient.
21. The method of claim 16 , wherein the formulation is administered intravenously, intraarterially, intraperitoneally, intramuscularly, intravascularly, subcutaneously, by injection, by infusion, by continuous infusion, or via a catheter.
22. The method of claim 16 , wherein the subject has previously been treated for cystinuria and the formulation is administered to prevent the recurrence of cystinuria.
23. The method of claim 16 , further comprising administering at least a second cystinuria therapy to the subject.
24. The method of claim 23 , wherein the second cystinuria therapy is a surgical therapy or a shock wave therapy.
25. The method of claim 23 , wherein the second cystinuria therapy comprises an agent or drug selected from the group consisting of: bicarbonate, tris-hydroxymethylene-aminomethane (tromethamine-E), acetylcysteine, D-penicillamine, α-mercaptopropionylglycine, and captopril.
26. The method of claim 16 , wherein the method reduces the level of cysteine and/or cystine in the subject's plasma and/or serum.
27. The method of claim 16 , wherein the method reduces the level of cysteine and/or cystine in the subject's urine.
28. The method of claim 16 , wherein the method prevents the formation of cystine stones in the subject's urinary tract.
29. The method of claim 16 , wherein the method prevents the formation of cystine stones in the subject's kidneys.
30. The method of claim 16 , wherein the method reduces the number of cystine stones in the subject's kidneys.
31. The isolated, modified CGL enzyme of claim 1 , wherein the modified CGL enzyme is at least 95% identical to SEQ ID NO: 1.
32. The isolated, modified CGL enzyme of claim 1 , wherein the modified CGL has the sequence of SEQ ID NO: 6.
33. The isolated, modified CGL enzyme of claim 1 , wherein the modified CGL enzyme has a k cat /K M for L-cystine and/or L-cysteine that is greater than the k cat /K M of human cystathionine-γ-lyase.
34. The isolated, modified CGL enzyme of claim 1 , wherein the modified CGL enzyme has a k cat /K M for L-cystine that is greater than 10,000 s −1 M −1 and/or wherein the modified CGL enzyme has a k cat /K M for L-cysteine that is greater than 1,000 s −1 M −1.